Stockscreener 앱 받기
7.15
3.47%
0.24
시간 외 거래:
7.15
전일 마감가:
$6.91
열려 있는:
$6.99
하루 거래량:
1,335
Relative Volume:
0.01
시가총액:
$4.21M
수익:
-
순이익/손실:
$-8.28M
주가수익비율:
-1.286
EPS:
-5.56
순현금흐름:
$-7.99M
1주 성능:
+4.84%
1개월 성능:
-18.10%
6개월 성능:
-34.82%
1년 성능:
-61.03%
1일 변동 폭
$6.99
$7.23
1주일 범위
$6.625
$7.85
52주 변동 폭
$5.01
$54.95
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile
명칭
Quoin Pharmaceuticals Ltd Adr
전화
97299741444
주소
23 HATA'AS STREET, KFAR SABA
QNRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QNRX
Quoin Pharmaceuticals Ltd Adr
|
7.15 | 4.33M | 0 | -8.28M | -7.99M | -5.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Quoin Pharmaceuticals Ltd Adr 주식(QNRX)의 최신 뉴스
Quoin (QNRX) Q2 Loss Beats Estimates - The Motley Fool
Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - The Globe and Mail
Quoin Pharmaceuticals stock rises after positive clinical updates - Investing.com India
Quoin Pharmaceuticals advances rare disease pipeline with two active trials - Investing.com India
Quoin Pharmaceuticals advances rare disease pipeline with two active trials By Investing.com - Investing.com Nigeria
Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Price Down 2.9% – Here’s Why - Defense World
MINISO Group Holding Limited Unsponsored ADR (NYSE:MNSO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Quoin Pharmaceuticals CFO Gordon Dunn to depart following mutual agreement - Investing.com India
Quoin Pharmaceuticals (NASDAQ:QNRX) Trading Down 1.2% – Should You Sell? - Defense World
Quoin Pharmaceuticals receives FDA rare pediatric disease designation for QRX003 - Investing.com
FDA grants rare pediatric disease designation for Netherton syndrome drug - Investing.com
Quoin announces FDA clearance to initiate second whole body QRX003 NS study - TipRanks
FDA clears Quoin’s new Netherton syndrome study By Investing.com - Investing.com South Africa
FDA clears Quoin’s new Netherton syndrome study - Investing.com
Quoin Pharmaceuticals announces EMA grants ODD for QRX003 - TipRanks
Retail Buzz Intensifies Around Quoin Pharma Stock After Positive Pediatric Skin Study Data By Stocktwits - Investing.com India
Why Quoin Pharmaceuticals (QNRX) Stock Is Exploding Higher Wednesday - Benzinga
Quoin Pharmaceuticals announces initial positive clinical data for QRX003 - TipRanks
Quoin reports progress in pediatric skin disorder study By Investing.com - Investing.com India
Quoin Pharmaceuticals reports Q1 EPS ($6.50) vs ($38.73) last year - TipRanks
Quoin Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com India
Quoin Pharmaceuticals regains Nasdaq compliance - Investing.com
Quoin Pharmaceuticals regains compliance with Nasdaq minimum bid price rule - TipRanks
Quoin Pharmaceuticals regains Nasdaq compliance with bid price - Investing.com
Quoin Pharmaceuticals releases second episode of ‘Living with Netherton’ series - TipRanks
QNRX Stock Plummets to 52-Week Low of $0.17 Amid Market Struggles - Investing.com India
Upcoming Stock Splits This Week (April 7 to April 11) – Stay Invested - The Globe and Mail
Quoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirements By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirements - Investing.com
Quoin Pharmaceuticals reports positive clinical data for rare disease treatment - Investing.com India
Quoin Pharmaceuticals reports positive clinical data for rare disease treatment By Investing.com - Investing.com South Africa
What Is Going On With Quoin Pharmaceuticals Ltd ADR (NASDAQ: QNRX)? - stocksregister.com
QNRX Stock Plummets to 52-Week Low at $0.26 Amid Market Struggles By Investing.com - Investing.com South Africa
QNRX Stock Plummets to 52-Week Low at $0.26 Amid Market Struggles - Investing.com India
Quoin seeks patent for skin disease treatment QRX003 By Investing.com - Investing.com South Africa
Quoin seeks patent for skin disease treatment QRX003 - Investing.com India
QNRX Stock Plummets to 52-Week Low at $0.28 Amid Market Struggles - Investing.com India
QNRX Stock Plummets to 52-Week Low at $0.28 Amid Market Struggles By Investing.com - Investing.com South Africa
NVIDIA Corp (NVDA) Shares Up Despite Recent Market Volatility - The News Heater
Quoin Pharmaceuticals reports promising Netherton Syndrome treatment - Investing.com India
Stock Performance Spotlight: Quoin Pharmaceuticals Ltd ADR (QNRX) Ends the Day at 0.31, Down by -2.06 - The Dwinnex
Is Energy Services of America Corp (NASDAQ: ESOA) Poised For Further Gains At A 45.82% Distance From The Low? - Marketing Sentinel
Should You Expect Quoin Pharmaceuticals Ltd ADR (NASDAQ:QNRX) To Recover From Its 9.68% Gain From Highs? - Marketing Sentinel
ScanTech AI Systems Inc (NASDAQ: STAI) Gain Of 9.66% Compared To 52-Week Low; YTD Fall -84.49% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Now Is The Time To Build A Position In SolarBank Corporation (NASDAQ:SUUN) - Marketing Sentinel
Aurora Mobile Ltd ADR (NASDAQ: JG) Stock Gained 83.28% Over A Month – Any Room To Run? - Marketing Sentinel
PDD Holdings Inc ADR (NASDAQ: PDD): How To Buy And When To Buy And Its Performance & Trends - Marketing Sentinel
An Overview of Castellum Inc (AMEX: CTM)’s Stock Performance and Outlook - Marketing Sentinel
Quoin Pharmaceuticals launches Netherton awareness campaign - Investing.com
Why Should You Invest In Castellum Inc (AMEX: CTM)? - Marketing Sentinel
Quoin Pharmaceuticals Ltd Adr (QNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):